UroGen Pharma Ltd (URGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UroGen Pharma Ltd (URGN) has a cash flow conversion efficiency ratio of 0.363x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.33 Million) by net assets ($-105.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
UroGen Pharma Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read URGN liabilities breakdown for a breakdown of total debt and financial obligations.
UroGen Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UroGen Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WCON Electronics (Guangdong) Co. Ltd. A
SHE:301328
|
N/A |
|
Namchow Food Group (Shanghai) Co. Ltd.
SHG:605339
|
-0.011x |
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151
|
N/A |
|
B-Soft Co Ltd
SHE:300451
|
-0.006x |
|
Huachangda Intelligent Equipment Group Co Ltd
SHE:300278
|
0.033x |
|
Bata India Limited
NSE:BATAINDIA
|
0.174x |
|
CCP Contact Probe Co Ltd
TWO:6217
|
-0.041x |
|
Max Zipper Co Ltd
TWO:8932
|
0.193x |
Annual Cash Flow Conversion Efficiency for UroGen Pharma Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of UroGen Pharma Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see UroGen Pharma Ltd (URGN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-105.47 Million | $-162.44 Million | 1.540x | -85.99% |
| 2024-12-31 | $-8.80 Million | $-96.77 Million | 10.992x | +838.56% |
| 2023-12-31 | $-65.21 Million | $-76.38 Million | 1.171x | +19.53% |
| 2022-12-31 | $-89.36 Million | $-87.56 Million | 0.980x | +109.71% |
| 2021-12-31 | $8.41 Million | $-84.89 Million | -10.091x | -818.23% |
| 2020-12-31 | $96.36 Million | $-105.89 Million | -1.099x | -179.00% |
| 2019-12-31 | $180.30 Million | $-71.02 Million | -0.394x | +4.95% |
| 2018-12-31 | $90.09 Million | $-37.33 Million | -0.414x | -196.64% |
| 2017-12-31 | $68.52 Million | $-9.57 Million | -0.140x | -154.38% |
| 2016-12-31 | $16.31 Million | $4.19 Million | 0.257x | +161.41% |
| 2015-12-31 | $17.15 Million | $-7.17 Million | -0.418x | +64.76% |
| 2014-12-31 | $3.47 Million | $-4.12 Million | -1.187x | -27.26% |
| 2013-12-31 | $2.74 Million | $-2.56 Million | -0.933x | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more